Aurora Spine Receives Australian TGA Clearance for ZIP Ultra(TM) MIS Interspinous Fusion System

Aurora Spine Corporation (TSX VENTURE:ASG) announced today that it has received
Australian Therapeutic Goods Administration (TGA) clearance for the ZIP
Ultra(TM) Interspinous Fusion System. Providing surgeons and patients with next
generation technology, the ZIP is a minimally invasive (MIS) spinal fixation
device for spinal fusion and was developed as an alternative to the pedicle
screw systems prevalent in the market.


The ZIP Ultra Interspinous Fusion System is listed on the Australian Register of
Therapeutic Goods (ARTG #219670) website. The Therapeutic Goods Administration
(TGA) is part of the Australian Government Department of Health. The TGA is
responsible for regulating therapeutic goods, including medicines, medical
devices and blood and blood products supplied in Australia.


"The receipt of the Australian Therapeutic Goods Administration (TGA) clearance
is a significant step forward in Aurora Spine's expansion into the global
Minimally Invasive Spinal Device market," says Brent Johnston, Chief
Commercialization Officer of Aurora Spine. "Aurora Spine will continue to strive
to bring improved fusion technology to patients and position itself as a leader
in spinal technology."


About Aurora Spine

Aurora Spine is an early stage company focused on bringing new solutions to the
spinal implant market through a series of innovative, minimally invasive,
regenerative spinal implant technologies.


Forward-Looking Statements

This news release contains forward-looking information that involves substantial
known and unknown risks and uncertainties, most of which are beyond the control
of Aurora Spine, including, without limitation, those listed under "Risk
Factors" and "Cautionary Statement Regarding Forward-Looking Information" in
Aurora Spine's final prospectus (collectively, "forward-looking information").
Forward-looking information in this news release includes information concerning
the proposed marketing and commercialization of Aurora Spine's products in
certain global markets. Aurora Spine cautions investors of its securities about
important factors that could cause Aurora Spine's actual results to differ
materially from those projected in any forward-looking statements included in
this news release. Any statements that express, or involve discussions as to,
expectations, beliefs, plans, objectives, assumptions or future events or
performance are not historical facts and may be forward-looking and may involve
estimates, assumptions and uncertainties which could cause actual results or
outcomes to differ unilaterally from those expressed in such forward-looking
statements. No assurance can be given that the expectations set out herein will
prove to be correct and, accordingly, prospective investors should not place
undue reliance on these forward looking statements. These statements speak only
as of the date of this press release and Aurora Spine does not assume any
obligation to update or revise them to reflect new events or circumstances.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Aurora Spine Corporation
Trent Northcutt
President and Chief Executive Officer
(760) 424-2004


Aurora Spine Corporation
Eric Fronk
Chief Financial Officer
(760) 424-2004
www.auroraspine.us

Aurora Spine (TSXV:ASG)
過去株価チャート
から 4 2024 まで 5 2024